Advanced search×

European Neuropsychopharmacology

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Sciencedirect, Gale, Ingenta, CSA, Rcgp, and Proquest

  1. Abnormal thermoregulation in drug-free male schizophrenia patients.

    European Neuropsychopharmacology 11(4):285 (2001) PMID 11532382

    We hypothesized that a standardized exercise-heat tolerance test [two 50-min bouts of walking a motor-driven treadmill at 40 degrees C (relative humidity=40%)] would reveal abnormal thermoregulation in drug-free schizophrenia patients. Six drug-free schizophrenia outpatients and seven healthy compar...
  2. Pindolol can be effectively given once or twice daily for augmentation in psychiatric patients.

    European Neuropsychopharmacology 10(6):511 (2000) PMID 11115742

  3. Neuroimaging of serotonin uptake sites and antidepressant binding sites in the thalamus of humans and 'higher' animals.

    European Neuropsychopharmacology 9(6):537 (1999) PMID 10625123

    This review presents the results of in vitro, ex vivo and in vivo studies carried out primarily for identifying serotonin uptake sites and/or antidepressant binding sites in the brain of humans and 'higher' animals, namely nonhuman primates and pigs. Five lines of evidence are considered. First, stu...
  4. Missing action of carbamazepine on postsynaptic GABA-responses of hippocampal CA3-neurons (slice, guinea pig).

    European Neuropsychopharmacology 8(4):353 (1998) PMID 9928928

    Conflicting data exist concerning the interaction of carbamazepine (CBZ) and GABA-receptors involved in the pathophysiology of neuropsychiatric disorders. The present study reveals that CBZ failed to alter membrane potential fluctuations mediated by an activation of postsynaptic GABA(A)- and GABA(B)...
  5. Dizocilpine (MK-801) and tetrodotoxin influence accumbal dopamine release evoked by intrapallidal morphine.

    European Neuropsychopharmacology 8(1):47 (1998) PMID 9452940

    We examined whether changes in accumbal dopamine and its metabolites produced by intrapallidal morphine a) are associated with local excitatory amino acid neurotransmission b) are determined by impulse propagation in dopamine neurons and c) are observed both ipsi- and contralateral to the morphine a...
  6. Tianeptine and alcohol dependence.

    European Neuropsychopharmacology 7 Suppl 3:S347 (1997) PMID 9405962

    Several arguments are in favour of the use of antidepressant drugs in alcohol-dependent patients, especially those acting on the serotoninergic system: (1) neurochemical data indicate the interaction between alcohol and 5-HT metabolism, (2) pharmacological studies show an improvement in the behaviou...
  7. The effects of antidepressants on psychomotor function with particular reference to reboxetine.

    European Neuropsychopharmacology 7 Suppl 1:S17 (1997) PMID 9169307

    This review assesses the relative efficacy and side-effect profile of the currently available treatment options for major depression and the new selective noradrenergic agent, reboxetine. The effects of these treatments on psychomotor function are reviewed using: choice reaction time (CRT) and criti...
  8. ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia.

    European Neuropsychopharmacology 24(10):1698 (2014) PMID 25108314

    We recently identified ASP5736, (N-(diaminomethylene)-1-(3,5-difluoropyridin-4-yl)-4-fluoroisoquinoline-7-carboxamide (2E)-but-2-enedioate), a novel antagonist of 5-HT5A receptor, and here describe the in vitro and in vivo characterization of this compound. ASP5736 exhibited a high affinity for the...
  9. Glutamate-mediated excitotoxicity in schizophrenia: a review.

    European Neuropsychopharmacology 24(10):1591 (2014) PMID 25159198

    Findings from neuroimaging studies in patients with schizophrenia suggest widespread structural changes although the mechanisms through which these changes occur are currently unknown. Glutamatergic activity appears to be increased in the early phases of schizophrenia and may contribute to these str...
  10. The expression of contextual fear conditioning involves activation of a NMDA receptor-nitric oxide-cGMP pathway in the dorsal hippocampus of...

    European Neuropsychopharmacology 24(10):1676 (2014) PMID 25174523

    We observed a reduction of contextual fear conditioning after dorsal hippocampus administration of either the neuronal NO synthase inhibitor N-propyl-L-arginine, the NO scavenger c-PTIO or the guanylate cyclase inhibitor ODQ. Therefore, the present findings suggest the possible existence of a dorsal...